Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Courses Quicksearch

Search Now!

Courses


Course List
  • Breaking Barriers: Improving Health Care Access for Patients with Pulmonary Hypertension

    Course ID: 2914
    Course Author: Arunabh Talwar
    Course Author: Vinicio de Jesus Perez

    This previously recorded live webinar features two of the world's foremost medical professionals, Arunabh Talwar, M.D. and Vinicio de Jesus Perez, M.D., who address topics in healthcare access for PH patients. This webinar focuses on the unique barriers to healthcare created by socioeconomic status and how this can affect patient care.


  • FDA-Approved Treatments for WHO Group 1 PH (PAH)

    Course ID: 2933
    Course Author: Vallerie McLaughlin

    WHO Group 1 PH Treatment Course Image
    Since 1995, more than a dozen WHO Group 1 PH (PAH, pulmonary arterial hypertension) targeted oral, inhaled, and infused therapies have been approved by the U.S. Food & Drug Administration. In this session, the mechanistic pathways of current FDA-approved targeted therapies, clinical considerations in selecting an initial PAH therapy, and goals of medical therapy will be discussed.


  • How to Follow Up with Your Patient

    Course ID: 2938
    Course Author: Peter Leary

    How to Follow-up with Your Patient Course Image
    This educational activity will allow participants to a) summarize risk stratification for the PH patient; b) describe recommended measures used in clinic to monitor disease progression; and c) summarize guideline recommendations on follow-up of the low-, moderate-, and high-risk patient.


  • How to Know When to Escalate PAH Therapy

    Course ID: 2960
    Course Author: Ronald Oudiz

    How to Know When To Escalate Therapy - Ron Oudiz,
    At the conclusion of this CME educational activity, participants will be able to describe recommended measures used to monitor disease progression; describe risk stratification in PAH; compare initial treatment strategies for low-, moderate-, and high-risk patients; and compare two expert consensus recommendations on PAH clinical management.


  • How to Know Your Patient Is Optimally Managed

    Course ID: 2949
    Course Author: Zeenat Safdar

    Optimal Management of PH Course Image
    Despite the robust therapeutic development since the 1990s, pulmonary hypertension (PH) remains a progressive, incurable disease. In this CME educational activity, Zeenat Safdar, MD, MS, reviews a) the clinical measures correlated with PH disease progression; and b) summarizes expert recommendations for following a stable PH patient.


  • Management of PH in the ICU

    Course ID: 2935
    Course Author: Todd Bull

    Management of PH in the ICU by Todd Bull, MD Cours
    WHO Group 1 PH (PAH, pulmonary arterial hypertension) is a rare, progressive disease characterized by increased pulmonary artery pressure and pulmonary vascular resistance (PVR). Increases in PVR places great stress on the right ventricle, normally a thin-walled, trabeculated, roughly triangulated structure. It is designed to pump into a low-impedance, high-capacitance pulmonary circulation system, which is not the case in PAH. Acutely ill patients need to hemodynamic compromise addressed quickly and effectively, to restore oxygenation, treat volume overload, and restore organ perfusion. Frequently employed strategies—including systemic blood pressure, cardiac output, hypervolemic, arrhythmia, ventilator management—should be approached differently given the high-impedance, low-capacitance nature of the diseased pulmonary circulation to improve patient outcomes. This session will review the normal function of the pulmonary vascular bed; describe the impact of sudden increases in RV after load on cardiac output; describe the impact of hypercarbia, hypoxia, and mechanical ventilation on PVR; discuss two common cardiac arrhythmias that can contribute to critical illness in patients with PAH; and discuss strategies to enhance RV-pulmonary artery interaction in critical illness.


  • PH In Its Most Common Forms: Clinical Vignettes for WHO Groups 1, 2, and 4

    Course ID: 2915
    Course Author: Vinicio de Jesus Perez
    Course Author: Bonnie Hudak
    Course Author: Tim Lahm

    This information-intensive, clinical vignette provides an overview of pulmonary hypertension as it most commonly presents itself using clinical case studies. This previously recorded live webinar presents and examines WHO Groups I, II, and IV, offering an interesting perspective on topics in health care barriers, common diagnostic pitfalls, and the complexities of pediatric PH.


  • Pulmonary Function Testing in PH

    Course ID: 2971
    Course Author: James Lamberti

    Pulmonary Function Testing in PH Course Image
    Pulmonary function testing is a series of tests that measure how well the lungs take in and exhale air, and how efficiently they transfer oxygen into the blood. Following participation in this webinar, hosted by PHA Online University, participants will be able to understand the role of pulmonary function tests in the evaluation of a patient with PH, classify pulmonary function test abnormalities as obstructive or restrictive, and define the typical abnormalities of pulmonary function in patients with idiopathic PAH.


  • Pulmonary Hypertension and RV Failure in the ICU

    Course ID: 2972
    Course Author: Steven Pugliese

    Pulmonary Hypertension and RV Failure in the ICU C
    Following participation in this webinar, hosted by PHA Online University, participants will be able to utilize techniques to determine etiology of shock state; understand the roles of inotropes, vasopressors, and pulmonary vasodilators in acute right heart failure; discuss an approach to arrhythmias and mechanical ventilation in decompensated right heart failure; and discuss the role of mechanical circulatory support in right heart failure.


  • Variety is the Spice of Life: Combination Therapy for PAH

    Course ID: 2724
    Course Author: Martha Kingman
    Course Author: Steven Nathan

    In this session we will discuss expert consensus guidelines for the use of combination therapy in PAH. We will briefly review the combination therapy clinical trial data to date including results of the recent AMBITION trial. We will also discuss some drug-drug interactions between PH medications.


  • WHO Group 1 PH (PAH)

    Course ID: 2937
    Course Author: Anna Hemnes

    WHO Group 1 PH (PAH) Course Image
    Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension (PH) characterized by increases in both pulmonary arterial pressure and pulmonary vascular resistance (PVR). This educational activity will help participants a) differentiate PAH from other forms of PH; b) integrate diagnostic tests to improve accuracy in PAH diagnosis; c) describe risk factors for developing PAH; and d) recognize outcome differences between associated PAH and idiopathic/heritable PAH.


  • WHO Group 4 PH (CTEPH Treatment): Surgical vs. Medical

    Course ID: 2936
    Course Author: Richard Channick

    WHO Group 4 PH (CTEPH) Treatment: Surgical vs. Med
    For more than two decades, WHO Group 4 PH (CTEPH, chronic thromboembolic pulmonary hypertension) has been treated surgically through pulmonary thromboendarterectomy (PTE). In late 2013, riociguat was approved by the U.S. Food & Drug Administration (FDA) for the treatment of inoperable or PH occurring post-PTE. Following this approval, expert consensus guidelines on the diagnosis and treatment of PH have incorporated medical management of these specific PH patients into the treatment algorithm. However, PTE remains the recommended intervention in patients deemed operable as it can hemodynamically stabilize correctly selected patients. These guidelines, however, remain vague about the definition of operability as it relies on the technical abilities of the surgical and medical multidisciplinary teams and a paucity of long-term, multi-center outcomes data. This session seeks to a) describe the role of CT angiography in assessing surgical accessibility in CTEPH patients; b) discern operable versus inoperable CTEPH; interpret the surgical classification system for CTEPH; d) explain the benefits of PTE; and e) discuss the therapeutic options for those patients with inoperable or recurrent CTEPH, including PH-targeted medical therapy and/or balloon pulmonary angioplasty.


  • WHO Group 4 PH (CTEPH)

    Course ID: 2934
    Course Author: William Auger

    WHO Group 4 PH (CTEPH) Course Image
    WHO Group 4 PH (CTEPH, chronic thromboembolic pulmonary hypertension) is a rare disease characterized by a mean pulmonary artery pressure (mPAP) = 25 mmHg, pulmonary artery occlusion pressure = 15 mmHg, and chronic, organized emboli in the pulmonary artery. In this session, the CTEPH clinical definition, the role of screening in all PH patients, risk factors for developing CTEPH, and treatment options will be discussed.